title: Progressing preclinical drug candidates: strategies on preclinical safety studies and the quest for adequate exposure.
abstract: Drug discovery lead optimization teams face many diverse challenges in the search for drug development candidates. This includes understanding the toxicology profile of a candidate, and some strategies call for in vivo preclinical safety studies to be moved increasingly earlier in the discovery phase to increase the likelihood of success in development. One of the final hurdles in these pursuits is achieving adequate exposure to support safety margins for human clinical trials. In this article, we describe several strategies on early toxicology studies along with various enabling formulation methods that can be employed to achieve optimal oral absorption. These two elements of research together can significantly increase the speed preclinical drug candidates can move through development, and the overall probability of success in identifying viable new drugs.
authors.affiliation: Merck Research Laboratories, 770 Sumneytown Pike, West Point, PA 19486, USA. john_higgins3@merck.com
authors.forename: John
authors.initials: J
authors.lastname: Higgins
authors.forename: Mark E
authors.initials: ME
authors.lastname: Cartwright
authors.forename: Allen C
authors.initials: AC
authors.lastname: Templeton
mesh_terms: D000818:Animals; D004353:Drug Evaluation, Preclinical; D064420:Drug-Related Side Effects and Adverse Reactions; D006801:Humans